Announcements Trials

Browse Landscape

Phase

Phase 3 5 Phase 2 2 Phase NA 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 16 Neoplasm Metastasis 13 Squamous Cell Carcinoma of Head and Neck 12 Prostatic Neoplasms 11 Neoplasms 11 Breast Neoplasms 9 Ovarian Neoplasms 8 Lung Neoplasms 8 Leukemia, Myeloid, Acute 8 Recurrence 7 Myasthenia Gravis 7 Head and Neck Neoplasms 7 Stomach Neoplasms 6 Colorectal Neoplasms 6 Pancreatic Neoplasms 5 Oropharyngeal Neoplasms 5 Lymphoma, Large B-Cell, Diffuse 5 Fatigue 5 Urinary Bladder Neoplasms 4 Mouth Neoplasms 4 Melanoma 4 Fallopian Tube Neoplasms 4 Endometrial Neoplasms 4 Colonic Neoplasms 4 Cholangiocarcinoma 4 Rectal Neoplasms 3 Peritoneal Neoplasms 3 Laryngeal Neoplasms 3 Hypopharyngeal Neoplasms 3 Glioblastoma 3

Interventions

tucatinib 1 Trastuzumab 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × HER2-positive Breast Cancer × 90 days × Clear all

NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡